Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.45 |
| ▸ | ADRA2A | P08913 | 5/20 | 0.45 |
| ▸ | TDP2 | O95551 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29506344 | 1.00 | PNMT (0.45) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL4336912 | 0.81 | CA1 (0.46) | PNMTADRA2ATDP2LMNAMEN1 | |
| Ammonia Solution, Strong SCHEMBL29113467 | 0.79 | PNMT (0.45) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL2061978 | 0.79 | PNMT (0.53) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL8311228 | 0.79 | PNMT (0.42) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL14220267 | 0.76 | PNMT (0.41) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL14053944 | 0.75 | ALDH1A1 (0.39) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL14053942 | 0.75 | ALDH1A1 (0.39) | PNMTADRA2ATDP2LMNAMEN1 | |
| SCHEMBL15541888 | 0.74 | RAB9A (0.41) | TDP2LMNAMEN1MAPTRAB9A | |
| SCHEMBL18595788 | 0.74 | PNMT (0.46) | PNMTADRA2ATDP2LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2023-01-19 | — | — | US | disclosed |
| EP-3986559-A1 | NEW COMPOUNDS AND METHODS | BenevolentAI Bio Limited (GB) | 2022-04-27 | — | — | EP | disclosed |
| CN-114340734-A | Novel compounds and methods | 博善人工智能生物科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2020260871-A1 | NEW COMPOUNDS AND METHODS | BENEVOLENTAI BIO LIMITED (GB) | 2020-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014226-A1 | NEW COMPOUNDS AND METHODS | ABL2, ABL1, ALK | PNMT 1346/4885ADRA2A 1248/4885TDP2 1935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.